Literature DB >> 17675338

MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation.

Maria V Guijarro1, Wolfgang Link, Aránzazu Rosado, Juan F M Leal, Amancio Carnero.   

Abstract

MAP17 is a non-glycosylated membrane-associated protein that has been shown to be over-expressed in human carcinomas, suggesting a possible role of this protein in tumorigenesis. However, very little is known about the molecular mechanism mediating the possible tumor promoting properties of MAP17. To analyze the effect of MAP17 on cell survival, we used Rat1 fibroblasts model where Myc over-expression promotes apoptosis in low serum conditions. In the present work, we report that over-expression of MAP17 protects Rat1a fibroblasts from Myc-induced apoptosis through reactive oxygen species (ROS)-mediated activation of the PI3K/AKT signaling pathway. MAP17-mediated survival was associated with absence of Bax translocation to the mitochondria and reduced caspase-3 activation. We show that a fraction of PTEN undergoes oxidation in MAP17-over-expressing cells. Furthermore, activation of AKT by MAP17 as measured by Thr308 phosphorylation was independent of PI3K activity. Importantly, modulation of ROS by antioxidant treatment prevented activation of AKT, restoring the level of apoptosis in serum-starved Rat1/c-Myc fibroblasts. Finally, over-expression of a dominant-negative mutant of AKT in MAP17-expressing clones makes them sensitive to serum depletion. Our data indicate that MAP17 protein activates AKT through ROS and this is determinant to confer resistance to Myc-induced apoptosis in the absence of serum.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675338     DOI: 10.1093/carcin/bgm154

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  14 in total

1.  PDZK1-interacting protein 1 (PDZK1IP1) traps Smad4 protein and suppresses transforming growth factor-β (TGF-β) signaling.

Authors:  Souichi Ikeno; Naoko Nakano; Keigo Sano; Takashi Minowa; Wataru Sato; Ryosuke Akatsu; Nobuo Sakata; Nobutaka Hanagata; Makiko Fujii; Fumiko Itoh; Susumu Itoh
Journal:  J Biol Chem       Date:  2019-02-04       Impact factor: 5.157

2.  Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma.

Authors:  B Amend; J Hennenlotter; M Scharpf; S Kruck; U Kuehs; E Senger; A S Merseburger; M A Kuczyk; K D Sievert; A Stenzl; J Bedke
Journal:  World J Urol       Date:  2011-08-07       Impact factor: 4.226

3.  Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence.

Authors:  Ekaterini Christina Tampaki; Athanasios Tampakis; Afroditi Nonni; Markus von Flüe; Efstratios Patsouris; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

4.  MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2.

Authors:  Michael J Coady; Abdulah El Tarazi; René Santer; Pierre Bissonnette; Louis J Sasseville; Joaquim Calado; Yoann Lussier; Christopher Dumayne; Daniel G Bichet; Jean-Yves Lapointe
Journal:  J Am Soc Nephrol       Date:  2016-06-10       Impact factor: 10.121

5.  MAP17 contributes to non-small cell lung cancer progression via suppressing miR-27a-3p expression and p38 signaling pathway.

Authors:  Qian Liang; Huan Zhang
Journal:  Cancer Biol Ther       Date:  2020-12-07       Impact factor: 4.742

6.  MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.

Authors:  Marco Perez; Juan M Praena-Fernandez; Blanca Felipe-Abrio; Maria A Lopez-Garcia; Antonio Lucena-Cacace; Angel Garcia; Matilde Lleonart; Guiovanna Roncador; Juan J Marin; Amancio Carnero
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

7.  MAP17, a ROS-dependent oncogene.

Authors:  Amancio Carnero
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

8.  MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer.

Authors:  María-José de Miguel-Luken; Manuel Chaves-Conde; Verónica de Miguel-Luken; Sandra Muñoz-Galván; José Luis López-Guerra; Juan C Mateos; Jerónimo Pachón; David Chinchón; Vladimir Suarez; Amancio Carnero
Journal:  Oncotarget       Date:  2015-05-20

9.  The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment.

Authors:  José M García-Heredia; Amancio Carnero
Journal:  Oncotarget       Date:  2017-10-06

10.  Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).

Authors:  Marco Perez; Javier Peinado-Serrano; Jose Manuel Garcia-Heredia; Irene Felipe-Abrio; Cristina Tous; Irene Ferrer; Javier Martin-Broto; Carmen Saez; Amancio Carnero
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.